The global aerosol delivery devices market was valued at $31,464 million in 2019, and is projected to reach $46,729 million by 2027, registering a CAGR of 4.9% from 2020 to 2027.
Aerosol delivery devices are used as rescue therapy or permanent treatment for respiratory diseases and non-respiratory diseases. It is the most advanced mode of drug administration treatment in which a drug is directly delivered to lungs to offer a systemic effect. Aerosol delivery devices are frequently used in treatment of asthma and COPD, which includes dry powder inhalers, metered dose inhalers, and nebulizers. Moreover, these devices are used in non-respiratory diseases such as diabetes, analgesia, and Parkinson’s disease.
Increase in prevalence of respiratory diseases such as COPD asthma and cystic fibrosis; surge in focus of manufacturers toward development of portable inhalation devices; increase in need for rescue medication treatment during sudden asthmatic attack; rise in demand for short-term, effective medication for asthma, and COPD; and government initiatives toward spread in awareness for COPD and asthma symptoms are the major factors that drive growth of the aerosol delivery devices market. In addition, rise in geriatric population, technological advancements in inhaler devices, rise in adoption of aerosol delivery devices by patients, rise in urbanization and pollution levels, and increase in number of R&D activities to develop ideal inhalation therapy are some other factors that contribute toward growth of the market. However, complications and side-effects associated with drug inhalation and high cost associated with nebulizers are expected to hinder growth of the market.
The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. According to a paper published by the Journal of Allergy and Clinical Immunology (JACI), in 2020, asthma and COPD patients appear to have increased their adherence to inhalation medications during the COVID-19. Moreover, some parts of developed countries such as the U.S. and the UK are experiencing shortages of bronchodilator inhalers such as albuterol inhalers, as hospitals are utilizing them for COVID-19 patients. Furthermore, according to data provided by the National Health Service (NHS) in 2020, number of salbutamol inhalers prescribed by general practitioners (GP) in England raised by 63% between February 2020 and March 2020. Thus, COVID-19 infection uplifted growth and opportunities for manufacturers of aerosol delivery devices during the forecast period.
Aerosol Delivery Devices Market Segmentation
The global aerosol delivery devices market is segmented into product, application, and distribution channel. By product, the market is categorized into dry powder inhalers, metered dose inhalers, and nebulizers. The dry powder inhalers segment is further bifurcated into single dose inhalers and multi dose inhalers. The metered dose inhalers segment is further divided into conventional pressurized inhalers and soft mist inhalers. The nebulizers segment is further categorized into jet nebulizers, ultrasonic wave nebulizers, and vibrating mesh nebulizers. On the basis of application, the market is segregated into asthma, chronic obstructive pulmonary disease, cystic fibrosis, and non-respiratory diseases. The non-respiratory diseases segment is further divided is into diabetes, analgesia, and Parkinson’s disease. Depending on distribution channel, the market is classified into retail pharmacies, hospital pharmacies, and e-commerce. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By Product
Metered Dose Inhaler segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.
Segment review
Presently, on the basis of product, the metered dose inhaler segment is the major revenue contributor, and is projected to grow significantly during the forecast period. Rise in prevalence of respiratory diseases such as asthma, COPD, cystic fibrosis, and other respiratory diseases, increase in demand for metered dose inhalers, surge in patient awareness toward effective & advanced respiratory devices, and technological advancements by respiratory device manufacturers in MDIs are the key factors that boost growth of the segment.
Depending on application, the asthma segment is the major shareholder in the global aerosol delivery devices market, owing to rise in patient awareness toward lung diseases, surge in demand for metered dose inhalers (MDIs), rise in smoking population, increase in air pollution, and surge in geriatric population facing chronic respiratory problems, and increase in prevalence of asthma globally.
By Distribution Channel
Retail Pharmacies segment is projected as one of the most lucrative segment.
Snapshot of Asia-Pacific aerosol delivery devices market
Asia-Pacific presents lucrative opportunities for key players operating in the aerosol delivery devices market, owing to large population base susceptible to asthma and COPD, increase in public awareness toward use and benefits of these devices and affordability of medical devices, development of the R&D sector; rise in healthcare reforms; and technological advancements in aerosol delivery devices products. Moreover, rise in demand for inhalers and nebulizers, and increase in demand for home healthcare devices contribute toward growth of the market. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high aerosol delivery devices market share is expected to drive growth of the aerosol delivery devices market in the region.
The key players profiled in this report include 3M Company, Aerogen, Inc., Glaxosmithkline Plc (GSK), Johnson & Johnson (Actelion Pharmaceuticals Ltd), Koninklijke Philips N.V., Merck & Co., Inc., Metall Zug Group (Clement Clarke International Ltd), Recipharm AB (Bespak), Teva Pharmaceutical Industries Limited, Vectura Group PLC, Gerresheimer AG, Heitkamp & Thumann KG (H&T Presspart), Iconovo AB, Merxin Ltd, and Nemera.
By Region
Asia-Pacific region would exhibit the highest CAGR of 6.4% during 2019-2026.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the aerosol delivery devices market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers aerosol delivery devices market analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the aerosol delivery devices market.
- A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global aerosol delivery devices market growth.
Aerosol Delivery Devices Market Report Highlights
| Aspects | Details |
 By Product |
|
 By Application |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | VECTURA GROUP PLC, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, AEROGEN, INC., GLAXOSMITHKLINE PLC (GSK), RECIPHARM AB (BESPAK), 3M COMPAN, METALL ZUG GROUP (CLEMENT CLARKE INTERNATIONAL LTD), JOHNSON & JOHNSON (ACTELION PHARMACEUTICALS LTD), MERCK & CO., INC., KONINKLIJKE PHILIPS N.V. |
Analyst Review
Aerosol delivery devices are used to deliver medicines to lungs and airways. These devices are mainly used to treat or prevent diseases of airways such as asthma, chronic obstructive pulmonary disease (COPD) or cystic fibrosis. Moreover, they are used to treat non respiratory diseases such as diabetes, analgesia, thyroid disorder, and others.
Increase in patient awareness toward inhalation therapies, increase in prevalence of asthma and COPD, technological advancements in inhaler devices, rise in demand for MDI & DPI, and rise in geriatric population are expected to drive growth of the aerosol delivery devices market. Furthermore, introduction of novel & advanced aerosol delivery devices propel the market growth. However, complications and side-effects associated with drug inhalation and higher cost of these devices hinder the growth of the market.
North America is expected to remain dominant during the forecast period, owing to increase in demand for aerosol delivery devices, rise in prevalence of chronic respiratory diseases, and presence of major key players along with R&D centers. Moreover, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to key players during the forecast period, owing to increase in patient awareness toward aerosol drug delivery treatment.
The total market value of Aerosol Delivery Devices market is $31,463.9 million in 2019.
The forcast period for Aerosol Delivery Devices market is 2020 to 2027
The market value of Aerosol Delivery Devices market in 2020 is $33,411.6 million.
The base year is 2019 in Aerosol Delivery Devices market
Top companies such as Glaxosmithkline Plc (GSK), Merck & co., Inc., Vectura Group Plc, Koninklijke Philips N.V., 3M Company, Teva Pharmaceutical Industries Limited, and Aerogen, Inc. held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
Metered dose inhalers segment is the most influencing segment owing to rise in prevalence of respiratory diseases such as asthma, COPD, cystic fibrosis, and other respiratory diseases, increase in demand for metered dose inhalers, surge in patient awareness toward effective & advanced respiratory devices, and technological advancements by respiratory device manufacturers in MDIs
The major factor that fuels the growth of the global Aerosol Delivery Devices market includes rise in prevalence of asthma, COPD, and other respiratory disorders, increase in smoking population, ease of administration of drug with aerosol delivery devices, rise in demand for metered-dose inhalers, technological advancements in inhaler devices, and rise in geriatric population, rise in adoption of aerosol delivery devices by patients, and increase in patient awareness toward inhalation therapy,
Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 7.1%. This is due to increase in prevalence of asthma, COPD and chronic respiratory diseases, improvement in healthcare facilities, increase in public awareness toward the use and benefits of these devices and affordability of medical devices.
Aerosol delivery devices are generally used as facilitators to provide drugs to patients. Inhaled medication through lungs is mostly provided to prevent or relieve asthma, COPD and other respiratory & non-respiratory ailments
Aerosol Delivery Devices products are used for direct deposition of inhaled medication to airway receptor sites
Loading Table Of Content...
